Editorial Commentary
Discernable differences in the genetic and molecular profile of cerebellar glioblastoma
Translational Cancer Research
2019;
8
(Suppl 6)
:S553-S558
.
(20 December 2019)
High predictability for identifying Lynch syndrome via microsatellite instability testing or immunohistochemistry in all Lynch-associated tumor types
Translational Cancer Research
2019;
8
(Suppl 6)
:S559-S563
.
(20 December 2019)
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Translational Cancer Research
2019;
8
(Suppl 6)
:S564-S568
.
(20 December 2019)
Revisiting anti-angiogenic therapy for recurrent glioblastoma
Translational Cancer Research
2019;
8
(Suppl 6)
:S569-S572
.
(20 December 2019)
Robotic surgery in early-stage endometrial cancer
Translational Cancer Research
2019;
8
(Suppl 6)
:S573-S576
.
(20 December 2019)
Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
Translational Cancer Research
2019;
8
(Suppl 6)
:S577-S579
.
(20 December 2019)
Pseudoprogression in low-grade glioma
Translational Cancer Research
2019;
8
(Suppl 6)
:S580-S584
.
(20 December 2019)
Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
Translational Cancer Research
2019;
8
(Suppl 6)
:S585-S588
.
(20 December 2019)
Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Translational Cancer Research
2019;
8
(Suppl 6)
:S589-S591
.
(20 December 2019)
Local therapy in patients with metastatic prostate cancer: a new standard of care?
Translational Cancer Research
2019;
8
(Suppl 6)
:S592-S594
.
(20 December 2019)
Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
Translational Cancer Research
2019;
8
(Suppl 6)
:S595-S597
.
(20 December 2019)
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
Translational Cancer Research
2019;
8
(Suppl 6)
:S598-S602
.
(20 December 2019)
Stepping in the right direction but still some ways to go
Translational Cancer Research
2019;
8
(Suppl 6)
:S603-S605
.
(20 December 2019)
New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology
Translational Cancer Research
2019;
8
(Suppl 6)
:S606-S611
.
(20 December 2019)
Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
Translational Cancer Research
2019;
8
(Suppl 6)
:S612-S617
.
(20 December 2019)
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Translational Cancer Research
2019;
8
(Suppl 6)
:S618-S620
.
(20 December 2019)
A mechanism for the tissue specificity in BAP1 cancer syndrome
Translational Cancer Research
2019;
8
(Suppl 6)
:S621-S624
.
(20 December 2019)
Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
Translational Cancer Research
2019;
8
(Suppl 6)
:S625-S627
.
(20 December 2019)
Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
Translational Cancer Research
2019;
8
(Suppl 6)
:S628-S632
.
(20 December 2019)
Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
Translational Cancer Research
2019;
8
(Suppl 6)
:S633-S635
.
(20 December 2019)
Conditional reprogramming technology: a new tool for personalized medicine in bladder cancer?
Translational Cancer Research
2019;
8
(Suppl 6)
:S636-S638
.
(20 December 2019)
N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples
Translational Cancer Research
2019;
8
(Suppl 6)
:S639-S641
.
(20 December 2019)
Letter to the Editor
“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
Translational Cancer Research
2019;
8
(Suppl 6)
:S642-S644
.
(20 December 2019)
News
Application of the CARE guideline as reporting standard in the Translational Cancer Research
Translational Cancer Research
2019;
8
(Suppl 6)
:S645
.
(20 December 2019)
Disclosure:
This supplement was published without any sponsorship or funding.
